Watch Ticker

Contineum Therapeutics, Inc. Class A Common Stock

Go to Contineum Therapeutics, Inc. Class A Common Stock Website

$6.00

0.21 (3.53%)

Live

Previous Close

$5.8

Day Range

$5.71 - $6.13

Previous Day Range

$5.71 - $6.01

Market Cap

$154.2 million USD

Day Vol.

86578

Previous Day Vol.

88091

Currency

USD

Primary Exchange

None

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIP...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Delveinsight - Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The pulmonary fibrosis market is driven by the increasing prevalence of the disease, especially idiopathic pulmonary fibrosis, among the aging population. Innovations in drug development and diagnostics, favorable reimbursement policies, and greater awareness are fueling market growth. The pipeline appears robust with over 110 active players working on 120+ pipeline drugs.

Related tickers: SNDX, PRTC, OTSKY, TRVI, SRPT, CTNM.

Read Full Article

Rapt Therapeutics, Inc. - RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced the appointment of Lori Lyons-Williams as the new chair of its board of directors, succeeding William Rieflin. Lyons-Williams is an industry veteran with over 20 years of experience in the pharmaceutical and biotech sectors.

Related tickers: RAPT, CTNM.

Read Full Article

Trending Tickers

Please sign in to view